Ranibizumab for macular edema following branch retinal vein occlusion

Abstract

Abstract Purpose To evaluate the efficacy and safeness of intraocular injections of Ranibizumab followed by grid photocoagulation in patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO). Methods Prospective study of 12 eyes with ME secondary to BRVO. Eyes were injected with 0.5 of Ranibizumab at the diagnosis time. Thirty days after the injection grid laser was applied in the area of capillary diffusion. Best corrected visual acuity (BCVA) and macular thickness measured by Cirrus‐HD Optical Coherence Tomography were evaluate, at the time of diagnosis, 1 month after injection an 3, 6, and 12 months after the laser. Results The mean BCVA at diagnosis was 0.34. One month after Ranibizumab BCVA was 0.53. Three,6 and 12 months after the laser the BCVA was 0.56, 0.65 and 0.73. The macular average thickness 1, 3, 6 and 12 months of treatment was 437, 300, 292 and 232 microns respectively. No safety events were found. Conclusion Single intraocular injection of Ranibizumab at the diagnosis of BRVO combined with grid photocoagulation could be an effectiveopton to accelerate visual recovery, improving the quality of life and VA since the first month of treatment.